Travere Therapeutics, Inc. TVTX
At closeNov 13, 2026, 5:25 PM EST
After hours · Nov 13, 5:25 PM ET
- YTD
- +32.56%
- 1 year
- +49.45%
- Market cap
- 4.86B
- Revenue (ttm)
- 651.03M
- Profit margin
- -18.66%
- EPS (ttm)
- -1.67
- Shares out
- 95.99M
- Forward P/E
- 9.35
- YTD return
- +32.56%
- 1-year return
- +49.45%
- Volume
- 708.20K
- Avg volume
- 1.82M
- Open
- 51.08
- Previous close
- 51.56
- Day's range
- 49.20 – 51.35
- 52-week range
- 26.79 – 67.52
- Beta
- 1.12
- Analysts
- Strong Buy
- Price target
- 73.43 (+45.0%)
- Earnings date
- Feb 18, 2027
5D +0.77 (+1.50%)
Key statistics
- Enterprise value
- 5.09B
- PEG ratio
- 0.00
- Price / sales
- 7.47
- Price / book
- 214.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 36.20%
- Free cash flow
- -64.79M
- Total cash
- 471.82M
- Total debt
- 616.16M
- Return on equity
- -321.22%
- Short % of float
- 12.90%
- 50-day average
- 56.25
- 200-day average
- 47.59
Analyst view
Consensus: strong buy
- Target (low)
- 62.00
- Target (mean)
- 73.43
- Target (high)
- 86.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate 0.8028.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | 0.4397 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.05545 | -0.55 | -0.49 | -891.88% |
| Aug 4, 2026 | Jun 30, 2026 | -0.13465 | -0.37 | -0.24 | -174.79% |
| May 4, 2026 | Mar 31, 2026 | -0.30 | -0.39 | -0.09 | -30.00% |
| Feb 19, 2026 | Dec 31, 2025 | 0.03 | 0.03 | 0.00 | 0.00% |
| Oct 30, 2025 | Sep 30, 2025 | -0.31 | 0.28 | +0.59 | +190.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2026 | Guggenheim | main | Buy | Buy |
| Sep 24, 2026 | Guggenheim | main | Buy | Buy |
| Sep 22, 2026 | Wedbush | reit | Outperform | Outperform |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- travere.com
News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX) 
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67 - Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72
Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78 
Travere Therapeutics Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Monday's After-Market Session 
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate - Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
10 Health Care Stocks Whale Activity In Today’s Session
Your note
Sign in to keep a note on TVTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.80% | 11,324,191 | 573.57M | Jun 29, 2026 |
| Blackrock Inc. | 8.36% | 8,020,663 | 406.25M | Jun 29, 2026 |
| FMR, LLC | 6.11% | 5,867,919 | 297.21M | Sep 29, 2026 |
| Bank of America Corporation | 4.76% | 4,568,341 | 231.39M | Jun 29, 2026 |
| State Street Corporation | 4.57% | 4,387,309 | 222.22M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.28% | 4,108,694 | 208.11M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.07% | 2,947,890 | 149.31M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.41% | 2,310,625 | 117.03M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.32% | 2,231,509 | 113.03M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 1.63% | 1,569,286 | 79.48M | Aug 30, 2026 |
| Vanguard Explorer Fund | 1.49% | 1,431,331 | 72.50M | Jul 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.43% | 1,376,986 | 69.74M | Sep 29, 2026 |